Expression of imatinib mesylate-targeted kinases in endometrial carcinoma

Imatinib mesylate is a tyrosine kinase inhibitor that specifically targets c-Kit, Abl, and platelet-derived growth factor receptor (PDGFR). It has been shown to be an effective treatment for patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). These cancers ar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2004-10, Vol.95 (1), p.32-36
Hauptverfasser:	Slomovitz, Brian M., Broaddus, Russell R., Schmandt, Rosemarie, Wu, Weiguo, Oh, Jonathan C., Ramondetta, Lois M., Burke, Thomas W., Gershenson, David M., Lu, Karen H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abl Antineoplastic Agents - pharmacology Benzamides Carcinoma, Endometrioid - drug therapy Carcinoma, Endometrioid - enzymology Carcinoma, Endometrioid - pathology Endometrial carcinoma Endometrial Neoplasms - drug therapy Endometrial Neoplasms - enzymology Endometrial Neoplasms - pathology Enzyme Inhibitors - pharmacology Female Humans Imatinib Mesylate Immunohistochemistry Paraffin Embedding PDGFR Phosphorylation Piperazines - pharmacology Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - biosynthesis Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins c-abl - antagonists & inhibitors Proto-Oncogene Proteins c-abl - biosynthesis Proto-Oncogene Proteins c-abl - metabolism Proto-Oncogene Proteins c-kit - biosynthesis Proto-Oncogene Proteins c-kit - metabolism Pyrimidines - pharmacology Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors Receptors, Platelet-Derived Growth Factor - biosynthesis Receptors, Platelet-Derived Growth Factor - metabolism Uterine papillary serous carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!